Lauria F, Rondelli D, Raspadori D, Zinzani P L, Benfenati D, Pileri S, Sabattini E, Tura S
Istituto di Ematologia L. e A. Seràgnoli, Università di Bologna, Italy.
Leuk Lymphoma. 1992 May;7(1-2):103-7. doi: 10.3109/10428199209053608.
The soluble Interleukin-2 Receptor (sIL-2R) serum levels were assessed in 42 patients with Hairy-Cell Leukemia (HCL) at diagnosis and after alpha-Interferon therapy and correlated with spleen size, peripheral hematological values, hairy cell index (HCI) and clinical response. Serum sIL-2R levels were significantly increased in all HCL patients, particularly in those with a higher HCI (> 0.50) and in non-splenectomized patients. Among the 26 HCL patients who were studied before and after 12 months of alpha-IFN treatment, 16 normalized the sIL-2R level and 10 did not. Our findings suggest that sIL-2R levels in HCL patients correlate with the splenic and bone marrow tumor burden as assessed by HCI. In addition patients with low levels of sIL-2R at diagnosis appear to have a better chance of achieving a good clinical response.
